Katherine Freeman
Family · Myrtle Beach, SCNPI 1346655834
Payments from drug & device makers
Across 117 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$500
- UCB, Inc.$440
- Novo Nordisk$245
- AbbVie$239
- Boehringer Ingelheim$151
- Radius Health, Inc.$98
- plus $793 from 24 others
What the payments were for
- Food & beverage$2,466100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 15 | $500 |
| UCB, Inc. | 24 | $440 |
| Novo Nordisk | 11 | $245 |
| AbbVie | 15 | $239 |
| Boehringer Ingelheim | 7 | $151 |
| Radius Health, Inc. | 5 | $98 |
| Amgen | 4 | $75 |
| Aurinia Pharma U.S., Inc. | 4 | $75 |
| Calliditas Therapeutics US Inc. | 3 | $69 |
| Lilly USA, LLC | 4 | $59 |
| Averitas Pharma Inc. | 2 | $58 |
| Bayer | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| GSK | 2 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Insulet Corporation | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Inari Medical, Inc. | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Exact Sciences | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Bausch Health US, LLC | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Halozyme Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$117
How this compares
$2,466 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $62,495 |
| FarxigaDapagliflozin Propanediol | 42 | $43,768 |
| JardianceEmpagliflozin | 27 | $34,465 |
| MounjaroTirzepatide | 14 | $31,047 |
| EliquisApixaban | 27 | $30,713 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $19,675 |
| GemtesaVibegron | 12 | $15,723 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 185 | $7,412 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $5,800 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,720 |
| SynthroidLevothyroxine Sodium | 61 | $5,079 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $4,517 |
| Atorvastatin Calcium | 375 | $4,430 |
| Dexlansoprazole DrDexlansoprazole | 19 | $4,116 |
| Gabapentin | 247 | $3,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $500 | $69,24376 claims |
| Novo NordiskOzempic | $245 | $62,49559 claims |
| PfizerEliquis, Premarin, Paxlovid | $15 | $35,09161 claims |
| Boehringer IngelheimJardiance | $151 | $34,46527 claims |
| Lilly USA, LLCMounjaro | $59 | $31,04714 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $27 | $15,72312 claims |
| GSKAnoro Ellipta | $33 | $5,72012 claims |
| AbbVieSynthroid | $239 | $5,07961 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.
Other family in Myrtle Beach
- Beverly MillerMyrtle Beach$10K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.